Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 31 clinical trials
Hamburg Edoxaban for Anticoagulation in COVID-19 Study (HERO-19)

Hero-19 aims to evaluate if an intensive anticoagulation strategy using Edoxaban on top of standard of care (SOC) of COVID-19 therapy is superior to SOC (in-hospital moderate anticoagulation

  • 4 views
  • 11 Mar, 2022
  • 8 locations
DOT HeartMate 3 Study

A prospective, single-center, randomized controlled trial of the feasibility and safety of apixaban in HeartMate 3 patients.

  • 0 views
  • 21 Apr, 2022
  • 1 location
CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19

mediating inflammation. A direct factor X inhibitor, namely edoxaban can act as prophylactic measure to mitigate the risk of venous and arterial thrombotic complications. Colchicine is an

  • 0 views
  • 05 Aug, 2021
  • 11 locations
Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease (EPIC-CAD)

This study evaluates the efficacy and safety of Edoxaban with the combination of edoxaban and antiplatelet in patients with stable CAD (coronary artery stenosis 50% on medical treatment or

vascular disease
percutaneous coronary intervention
atrial fibrillation
aspirin
coronary artery bypass
  • 51 views
  • 09 Feb, 2022
  • 8 locations
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) (ENRICH-AF)

To assess whether edoxaban (60/30 mg daily) compared to non-antithrombotic medical therapy (either no antithrombotic therapy or antiplatelet monotherapy) reduces the risk of stroke (composite of

vascular disease
fibrillation
anticoagulants
atrial fibrillation
stroke
  • 15 views
  • 16 Feb, 2022
  • 139 locations
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban and to compare the efficacy and safety of edoxaban against standard of care in pediatric subjects with confirmed VTE.

vitamin k
probe
venous thromboembolism
heparin therapy
anticoagulant therapy
  • 0 views
  • 12 May, 2022
  • 117 locations
Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study (ONCO DVT)

The purpose of this study is to determine the optimal duration of anticoagulation therapy (3 months versus 12 months) with direct oral anticoagulant (edoxaban) for isolated distal deep vein

thrombosis
venous thrombosis
clot
deep venous thrombosis of lower extremity
deep vein thrombosis
  • 15 views
  • 09 Feb, 2022
  • 1 location
Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery (Annexa-S)

Prospective, open-label clinical trial to evaluate the efficacy and safety of andexanet alfa patients who require urgent surgery that have been anticoagulated with the FXa (activated factor X) inhibitors.

enoxaparin
  • 0 views
  • 24 Feb, 2022
  • 30 locations
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG (PACES)

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying …

anticoagulation therapy
atrial fibrillation
aspirin
fibrillation
edoxaban
  • 112 views
  • 27 Apr, 2022
  • 43 locations
Effects of Edoxaban on Platelet Aggregation

: Analyze the role of edoxaban on platelet aggregation in SCAD patients. Methods and Results: This is a prospective, non-randomized, interventional study of SCAD patients taking low-dose

antiplatelet agents
aspirin
angiography
antiplatelet therapy
coronary angioplasty
  • 0 views
  • 22 Nov, 2021
  • 1 location